Alectos Therapeutics

Alectos Therapeutics is a privately held pharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics for the treatment of human disease. We focus on preclinical drug development, target validation, hit-to-lead optimization, and IND-enabling studies. Alectos develops innovative new strategies to address medical conditions for which there are no effective treatments.

Our most advanced program is directed towards development of first-in-class agents that modulate the O-GlcNAcase (OGA) enzyme as a disease-modifying therapy for treatment of Progressive Supranuclear Palsy, Alzheimer’s disease, and other neurodegenerative disorders; this program is partnered with Merck. As part of its pipeline, Alectos is also advancing discovery-stage programs in Parkinson’s disease and Niemann-Pick type C disease.